[ad_1]
Pharmaceutical Manufacturing Market
A new research document is added in HTF MI database of 130 pages, titled as ‘Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity’ with detailed analysis, Competitive landscape, forecast and strategies. Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Abbott Laboratories, Aenova Group, Amgen, AstraZeneca, Catalent Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Lonza Group, Lupin, Merck & Co., Inc., Novartis AG, Novo Nordisk, Pfizer, Inc., Roche, Sanofi SA, Takeda. The Market has witnessed continuous growth in the past few years and is projected to see some stability post Q2,2020 and may grow further during forecast year 2021-2026
Access sample report @ https://www.htfmarketreport.com/sample-report/3181039-asia-pacific-pharmaceutical-manufacturing-industry-2020-2027-by-formulation-route-of-administration-age-group-therapeutic-application-drug-type-distribution-channel-manufacturing-facility-and-country
Summary
Asia Pacific pharmaceutical manufacturing industry will grow by 14.8% annually with a total addressable market cap of $1,034.6 billion over 2021-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.
Highlighted with 33 tables and 63 figures, this 130-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Industry Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Industry Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.
Based on Formulation, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
Based on Route of Administration, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Oral Medicine
• Topical Medicine
• Parenteral Medicine
• Inhalations
• Other Routes of Administration
Based on Age Group, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Children & Adolescents
• Adults
• Geriatric
Based on Therapeutic Application, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Neurological Diseases
• Orthopedics
• Other Applications
Based on Drug Type, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Based on Distribution Channels, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Retail Channels
• Non-retail Channels
Based on Manufacturing Facility, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• In-house Facility
• Outsourced Facility
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories, Aenova Group, Amgen, AstraZeneca, Catalent Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Lonza Group, Lupin, Merck & Co., Inc., Novartis AG, Novo Nordisk, Pfizer, Inc., Roche, Sanofi SA, Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/3181039-asia-pacific-pharmaceutical-manufacturing-industry-2020-2027-by-formulation-route-of-administration-age-group-therapeutic-application-drug-type-distribution-channel-manufacturing-facility-and-country
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.2 Research Methodology 11
1.3 Executive Summary 17
2 Industry Overview and Dynamics 20
2.1 Industry Size and Forecast 20
2.2 Major Growth Drivers 26
2.3 Industry Restraints and Challenges 29
2.4 Emerging Opportunities and Industry Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Industry by Formulation 40
3.1 Industry Overview by Formulation 40
3.2 Tablets 42
3.3 Capsules 43
3.4 Injectable 44
3.5 Sprays 45
3.6 Suspensions 46
3.7 Powders 47
3.8 Other Formulations 48
4 Segmentation of Asia Pacific Industry by Route of Administration 49
5 Segmentation of Asia Pacific Industry by Age Group 56
6 Segmentation of Asia Pacific Industry by Therapeutic Application 61
7 Segmentation of Asia Pacific Industry by Drug Type 71
8 Segmentation of Asia Pacific Industry by Distribution Channels 76
9 Segmentation of Asia Pacific Industry by Manufacturing Facility 80
10 Asia-Pacific Industry 2020-2027 by Country 84
11 Competitive Landscape 100
….Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/3181039-asia-pacific-pharmaceutical-manufacturing-industry-2020-2027-by-formulation-route-of-administration-age-group-therapeutic-application-drug-type-distribution-channel-manufacturing-facility-and-country
It’s vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.
PR & Marketing Manager
HTF Market Intelligence Consulting Pvt. Ltd.
1-206-317-1218
Connect with us at LinkedIn | Facebook | Twitter
About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.
This release was published on openPR.
[ad_2]
